Identification of Common Differentially Expressed Genes in Urinary Bladder Cancer

Background Current diagnosis and treatment of urinary bladder cancer (BC) has shown great progress with the utilization of microarrays. Purpose Our goal was to identify common differentially expressed (DE) genes among clinically relevant subclasses of BC using microarrays. Methodology/Principal Findings BC samples and controls, both experimental and publicly available datasets, were analyzed by whole genome microarrays. We grouped the samples according to their histology and defined the DE genes in each sample individually, as well as in each tumor group. A dual analysis strategy was followed. First, experimental samples were analyzed and conclusions were formulated; and second, experimental sets were combined with publicly available microarray datasets and were further analyzed in search of common DE genes. The experimental dataset identified 831 genes that were DE in all tumor samples, simultaneously. Moreover, 33 genes were up-regulated and 85 genes were down-regulated in all 10 BC samples compared to the 5 normal tissues, simultaneously. Hierarchical clustering partitioned tumor groups in accordance to their histology. K-means clustering of all genes and all samples, as well as clustering of tumor groups, presented 49 clusters. K-means clustering of common DE genes in all samples revealed 24 clusters. Genes manifested various differential patterns of expression, based on PCA. YY1 and NFκB were among the most common transcription factors that regulated the expression of the identified DE genes. Chromosome 1 contained 32 DE genes, followed by chromosomes 2 and 11, which contained 25 and 23 DE genes, respectively. Chromosome 21 had the least number of DE genes. GO analysis revealed the prevalence of transport and binding genes in the common down-regulated DE genes; the prevalence of RNA metabolism and processing genes in the up-regulated DE genes; as well as the prevalence of genes responsible for cell communication and signal transduction in the DE genes that were down-regulated in T1-Grade III tumors and up-regulated in T2/T3-Grade III tumors. Combination of samples from all microarray platforms revealed 17 common DE genes, (BMP4, CRYGD, DBH, GJB1, KRT83, MPZ, NHLH1, TACR3, ACTC1, MFAP4, SPARCL1, TAGLN, TPM2, CDC20, LHCGR, TM9SF1 and HCCS) 4 of which participate in numerous pathways. Conclusions/Significance The identification of the common DE genes among BC samples of different histology can provide further insight into the discovery of new putative markers.

[1]  Heather J. Ruskin,et al.  Cross-Platform Microarray Data Normalisation for Regulatory Network Inference , 2010, PloS one.

[2]  N. Seki,et al.  CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer. , 2010, International journal of molecular medicine.

[3]  Jiaoti Huang,et al.  Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.

[4]  Weihong Zhao,et al.  Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549 , 2010, Journal of experimental & clinical cancer research : CR.

[5]  C. Cordon-Cardo,et al.  Molecular pathways of urothelial development and bladder tumorigenesis. , 2010, Urologic oncology.

[6]  K. Struhl,et al.  A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. , 2010, Cancer cell.

[7]  Terence P. Speed,et al.  Identification of Candidate Growth Promoting Genes in Ovarian Cancer through Integrated Copy Number and Expression Analysis , 2010, PloS one.

[8]  D. Spandidos,et al.  Yin Yang 1 expression in human tumors , 2010, Cell cycle.

[9]  F. Cross,et al.  The emerging role of APC/CCdh1 in controlling differentiation, genomic stability and tumor suppression , 2010, Oncogene.

[10]  J. Stanford,et al.  Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. , 2009, Cancer research.

[11]  Patricia A. Wood,et al.  THE CIRCADIAN CLOCK GENE PER1 SUPPRESSES CANCER CELL PROLIFERATION AND TUMOR GROWTH AT SPECIFIC TIMES OF DAY , 2009, Chronobiology international.

[12]  Joomyeong Kim,et al.  YY1 is autoregulated through its own DNA-binding sites , 2009, BMC Molecular Biology.

[13]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[14]  M. Burset,et al.  DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. , 2009, The Journal of urology.

[15]  F. Monzon,et al.  Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Giancarlo Castellano,et al.  The involvement of the transcription factor Yin Yang 1 in cancer development and progression , 2009, Cell cycle.

[17]  A. Zaravinos.  Yin Yang 1 as a prognostic factor , 2009, Cell cycle.

[18]  P. Kirschmeier,et al.  An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. , 2009, Toxicology.

[19]  B. Scheithauer,et al.  Rab3B immunoexpression in human pituitary adenomas , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[20]  Matthew L. Anderson,et al.  Relaxin Signaling in Uterine Fibroids , 2009, Annals of the New York Academy of Sciences.

[21]  W. Kassouf,et al.  Peroxisome proliferator-activated receptor γ in bladder cancer: A promising therapeutic target , 2009, Cancer biology & therapy.

[22]  I. Mills,et al.  Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. , 2009, Carcinogenesis.

[23]  M. Campbell,et al.  Elevated NCOR 1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells , 2009 .

[24]  Douglas G Altman,et al.  Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets , 2008, PLoS medicine.

[25]  I. Adcock,et al.  Hydrogen Peroxide Prolongs Nuclear Localization of NF-κB in Activated Cells by Suppressing Negative Regulatory Mechanisms* , 2008, Journal of Biological Chemistry.

[26]  A. Jacobsson,et al.  Steroid hormones control circadian Elovl3 expression in mouse liver. , 2008, Endocrinology.

[27]  J. S. Hunt,et al.  Growth Factors , Cytokines , Cell Cycle Molecules Signaling Pathways for B Cell-Activating Factor ( BAFF ) and a Proliferation-Inducing Ligand ( APRIL ) in Human Placenta , 2010 .

[28]  S. Hatakeyama,et al.  Involvement of Ymer in suppression of NF-kappaB activation by regulated interaction with lysine-63-linked polyubiquitin chain. , 2008, Biochimica et biophysica acta.

[29]  L. Sobin,et al.  The Staging of Cancer: A Retrospective and Prospective Appraisal , 2008, CA: a cancer journal for clinicians.

[30]  P. Evans,et al.  NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. , 2008, The Journal of biological chemistry.

[31]  Y. Furukawa,et al.  CDC20, a potential cancer therapeutic target, is negatively regulated by p53 , 2008, Oncogene.

[32]  Ana Dopazo,et al.  Codelink: an R package for analysis of GE healthcare gene expression bioarrays , 2007, Bioinform..

[33]  Dejan Juric,et al.  Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Petersen,et al.  The Mammalian Golgi Regulates Numb Signaling in Asymmetric Cell Division by Releasing ACBD3 during Mitosis , 2007, Cell.

[35]  F. Marks,et al.  Tumor promotion as a target of cancer prevention. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[36]  C. Hoang‐Vu,et al.  Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. , 2007, Advances in experimental medicine and biology.

[37]  M. Becich,et al.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process , 2007, BMC Cancer.

[38]  Jun Hua,et al.  Extending the loop design for two-channel microarray experiments. , 2006, Genetical research.

[39]  Heri Ramampiaro,et al.  GeneTools – application for functional annotation and statistical hypothesis testing , 2006, BMC Bioinformatics.

[40]  M. Wirth,et al.  Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR. , 2006, International journal of cancer.

[41]  Jianping Liu,et al.  Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF‐induced apoptosis of ovarian cancer cells OV‐90 , 2006, FEBS letters.

[42]  Maqc Consortium.  The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements , 2006, Nature Biotechnology.

[43]  Wei Wu,et al.  Comparison of normalization methods for CodeLink Bioarray data , 2005, BMC Bioinformatics.

[44]  Sudeshna Adak,et al.  Considerations in making microarray cross-platform correlations , 2005, 2005 IEEE Computational Systems Bioinformatics Conference - Workshops (CSBW'05).

[45]  S. Horvath,et al.  Expression of transcription factor Yin Yang 1 in prostate cancer. , 2005, International journal of oncology.

[46]  Bing Zhang,et al.  WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..

[47]  H. Nishioka,et al.  Significance of immunohistochemical expression of Rab3B and SNAP-25 in growth hormone-producing pituitary adenomas , 2005, Acta Neuropathologica.

[48]  Weihong Yan,et al.  Expression-based monitoring of transcription factor activity: the TELiS database , 2005, Bioinform..

[49]  Nicolas Stransky,et al.  Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. , 2005, Cancer research.

[50]  Seong-Jin Kim,et al.  Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1 , 2004, Cancer Research.

[51]  J. Ericsson,et al.  YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Rhee,et al.  The RING-H2-finger protein APC11 as a target of hydrogen peroxide. , 2004, Free Radical Biology & Medicine.

[53]  A. Lopez‐Beltran,et al.  Non-invasive urothelial neoplasms: according to the most recent WHO classification. , 2004, European urology.

[54]  R. Roeder,et al.  TIP30 Interacts with an Estrogen Receptor α-interacting Coactivator CIA and Regulates c-myc Transcription* , 2004, Journal of Biological Chemistry.

[55]  S. Grossman,et al.  Yin Yang 1 Is a Negative Regulator of p53 , 2004, Cell.

[56]  Mogens Kruhøffer,et al.  Gene Expression in the Urinary Bladder , 2004, Cancer Research.

[57]  Rolf Ackermann,et al.  Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder , 2004, Clinical Cancer Research.

[58]  Carole L Yauk,et al.  Comprehensive comparison of six microarray technologies. , 2004, Nucleic acids research.

[59]  Bing Zhang,et al.  GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies , 2004, BMC Bioinformatics.

[60]  A. Regev,et al.  Molecular analysis of transitional cell carcinoma using cDNA microarray , 2003, Oncogene.

[61]  J. Townsend,et al.  BMC Genomics BioMed Central Methodology article , 2003 .

[62]  L. Dyrskjøt.  Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics , 2003, Expert review of molecular diagnostics.

[63]  Wentian Li,et al.  Copyright © American Society for Investigative Pathology Gene Discovery in Bladder Cancer Progression using cDNA Microarrays , 2022 .

[64]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[65]  P. Hamilton,et al.  The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  S. Kakar,et al.  Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. , 2003, American journal of clinical pathology.

[67]  Partha S. Vasisht.  Computational Analysis of Microarray Data , 2003 .

[68]  Robert Tibshirani,et al.  Statistical methods for identifying differentially expressed genes in DNA microarrays. , 2003, Methods in molecular biology.

[69]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[70]  G. Churchill.  Fundamentals of experimental design for cDNA microarrays , 2002, Nature Genetics.

[71]  N. Socci,et al.  Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. , 2002, Cancer research.

[72]  X. Yi,et al.  Monitoring gene expression profile changes in bladder transitional cell carcinoma using cDNA microarray. , 2002, Urologic oncology.

[73]  S. Ghosh,et al.  The Phosphorylation Status of Nuclear NF-ΚB Determines Its Association with CBP/p300 or HDAC-1 , 2002 .

[74]  S. Ghosh,et al.  The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. , 2002, Molecular cell.

[75]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..

[76]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Hong Zhang,et al.  A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. , 2001, Cancer research.

[78]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[80]  M. Kruhøffer,et al.  Identification of gene expression patterns in superficial and invasive human bladder cancer. , 2001, Cancer research.

[81]  G. Church,et al.  A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression , 2000, Nature Genetics.

[82]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[83]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[84]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[85]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[86]  H. Grossman,et al.  Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer , 1999, Oncogene.

[87]  Jeng-Shin Lee,et al.  Everything you have ever wanted to know about Yin Yang 1...... , 1997, Biochimica et biophysica acta.

[88]  Holger Karas,et al.  TRANSFAC: a database on transcription factors and their DNA binding sites , 1996, Nucleic Acids Res..

[89]  Y Hochberg,et al.  Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. , 1995, Medical hypotheses.

[90]  D. Reese,et al.  A rationale for the loss of growth control during experimental bladder carcinogenesis. , 1979, Medical hypotheses.